T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients.
J. Int. AIDS Soc. 20:21865 (2017)
Bolduan S et al; licensee International AIDS Society. Introduction: Restriction factors (RFs) suppress HIV-1 in cell lines and primary cell models. Hence, RFs might be attractive targets for novel antiviral strategies, but their importance for virus control in vivo is controversial. Methods: We profiled the expression of RFs in primary blood-derived mononuclear cells (PBMC) from therapy-naïve HIV-1 patients and quantified infection. Results: Overall, there was no correlation between individual RF expression and HIV-1 status in total PBMC. However, we identified a T cell population with low levels of intracellular CD2 and reduced expression of SAMHD1, p21 and SerinC5. CD2 low T cells with reduced RF expression were markedly positive for HIV-1 p24. In contrast, CD2+ T cells were less infected and expressed higher levels of RFs. CD2 low T cell infection correlated with viral loads and was associated with HIV-1 disease progression. Conclusions: In untreated therapy naïve chronic HIV-1 patients, RF expression in T cells is associated with CD2 expression and seems to influence viral loads. Our study suggests that RFs help to control HIV-1 infection in certain T cells in vivo and supports the potential for RFs as promising targets for therapeutic intervention.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Hiv-1 ; In Vivo Relevance ; P21 ; Restriction Factors ; Risp ; Samhd1 ; Serinc5 ; Tetherin; Hepatitis-c Virus; In-vivo; Antiretroviral Activity; Immunodeficiency-virus; Elite Controllers; Host; Nef; Vpu; Surface; Samhd1
Keywords plus
Language
Publication Year
2017
Prepublished in Year
HGF-reported in Year
2017
ISSN (print) / ISBN
1758-2652
e-ISSN
1758-2652
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 20,
Issue: 1,
Pages: ,
Article Number: 21865
Supplement: ,
Series
Publisher
Springer
Publishing Place
Berlin ; Heidelberg
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-502700-006
G-502700-001
Grants
Copyright
Erfassungsdatum
2017-09-29